TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
NNNN

Anbio Biotechnology

Healthcare · Medical Instruments & Supplies

3.80$ -6.2% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Anbio Biotechnology (NNNN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.4% of the shares are freely tradable; institutional investors hold 4.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 4.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 90.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions NNNN
Name Stake (%) Shares Change (%) Date
Geode Capital Management, LLC 0.06 26,736 +3.8 06/30/2026
Bank of America Corp 0.03 13,419 +0.0 06/30/2026
BNP Paribas Arbitrage, SA 0.03 11,800 +13.5 06/30/2026
Marshall Wace Asset Management Ltd 0.03 11,502 +0.0 06/30/2026
Morgan Stanley - Brokerage Accounts 0.02 7,231 -1.5 06/30/2026
UBS Group AG 0.00 828 -86.9 06/30/2026
EverSource Wealth Advisors, LLC 0.00 187 -29.7 06/30/2026
Advisor Group Holdings, Inc. 0.00 77 +0.0 06/30/2026

Funds

Funds NNNN
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Intl Sm Cp ETF 0.06 25,736 +0.0 10/30/2026
Fidelity Nasdaq Composite Index 0.05 22,209 -16.9 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?